News | May 30, 2023
Jubilant Pharmova posts Q4FY23 consolidated loss at Rs. 97.84 Cr
The company has reported total income of Rs. 1682.45 crores during the period ended March 31, 2023
The company has reported total income of Rs. 1682.45 crores during the period ended March 31, 2023
Based on this inspection and the USFDA VAI classification, this facility is in compliance with regard to current good manufacturing practices (cGMP)
The company will submit an action plan on the observations and will engage with US FDA for next steps.
The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
The company has reported total income of Rs. 1612.60 crores during the period ended September 30, 2022.
The company has reported total income of Rs. 1463.03 crores during the period ended June 30, 2022.
he US FDA has issued six observations pursuant to the completion of the audit.
There is also a strong synergy between Jubilant and Greencure with respect to OTC portfolio which can be explored for R&D, online acceleration and offline distribution
The generic version of Sinequan, which is used for the treatment of anxiety, depression, and other target symptoms of psychoneurosis
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
Subscribe To Our Newsletter & Stay Updated
